Lapanix 250 mg (Lapatinib)

Product Name : Lapanix(Lapatinib)
Generic Name : Lapatinib
Formulation : Tablet
Available Pack Size : 150’s Pot
Available Strengths : 250 mg
Registrations : 08.07.2021

Product Description

What is Lapanix 250mg?

Lapanix 250mg has the main ingredient Lapatinib with the same content as a drug that helps users treat breast cancer effectively and with high safety. Lapanix 250mg has been tested, and put into use .in many countries.

Basic information of the drug Lapanix 250mg

  • Active ingredient: Lapatinib. 
  • Classification of active ingredients: Anti-cancer drugs, tyrosin kinase inhibitors.
  • Trade name: Lapanix 250mg
  • Dosage form: Tablets.
  • Product packaging: Box of 150 tablets.
  • Origin: Beacon - Bangladesh.

Ingredients 

  • Lapatinib 250mg.

Pharmacodynamic properties

  • Lapanix/Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase domains of both EGFR (ErbB1) and HER2 (ErbB2) receptors (estimated applied Ki values 3nM and 13nM, respectively) with slow rate of shutdown from these receptors (half-life greater than or equal to 300 min). Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models.

Interactions of Lapanix 250mg with other products

  • CYP3A4 inhibitors (eg, ketoconazole, itraconazole or grapefruit juice), midazolam, irinotecan & digoxin.
  • Inducers of CYP3A4 (eg, rifampin, carbamazepine, phenytoin).
  • Proton pump inhibitors (eg, esomeprazole). 
  • P-glycoprotein, breast cancer protein (BCRP) inhibitor,
  • Inducers, topotecan & rosuvastatin. 
  • Increased incidence & severity of adverse events with paclitaxel & docetaxel. 
  • CYP3A4 or CYP2C8 substrates.

Similar product

  • Femara 2.5mg
  • Aromasin 250mg
  • Nerlynx 40mg

 

简体中文繁體中文NederlandsEnglishFrançaisDeutschItalianoLatviešu valodaLietuvių kalbaEspañolTürkçeУкраїнська